[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2019086646A8 - Feline leukemia virus vaccine - Google Patents

Feline leukemia virus vaccine Download PDF

Info

Publication number
WO2019086646A8
WO2019086646A8 PCT/EP2018/080094 EP2018080094W WO2019086646A8 WO 2019086646 A8 WO2019086646 A8 WO 2019086646A8 EP 2018080094 W EP2018080094 W EP 2018080094W WO 2019086646 A8 WO2019086646 A8 WO 2019086646A8
Authority
WO
WIPO (PCT)
Prior art keywords
leukemia virus
feline leukemia
virus vaccine
vaccine
feline
Prior art date
Application number
PCT/EP2018/080094
Other languages
French (fr)
Other versions
WO2019086646A1 (en
Inventor
Ian Tarpey
Original Assignee
Intervet International B.V.
Intervet Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International B.V., Intervet Inc. filed Critical Intervet International B.V.
Priority to JP2020524369A priority Critical patent/JP2021501761A/en
Priority to US16/759,927 priority patent/US11311616B2/en
Priority to BR112020008957-5A priority patent/BR112020008957A2/en
Priority to EP18803572.9A priority patent/EP3706788A1/en
Priority to AU2018358077A priority patent/AU2018358077A1/en
Priority to RU2020118586A priority patent/RU2784533C2/en
Priority to CA3080427A priority patent/CA3080427A1/en
Publication of WO2019086646A1 publication Critical patent/WO2019086646A1/en
Publication of WO2019086646A8 publication Critical patent/WO2019086646A8/en
Priority to US17/698,205 priority patent/US12076392B2/en
Priority to JP2023135272A priority patent/JP2023159327A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides a vaccine for feline leukemia virus and methods of making and using the vaccine alone, or in combinations with other protective agents.
PCT/EP2018/080094 2017-11-06 2018-11-05 Feline leukemia virus vaccine WO2019086646A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2020524369A JP2021501761A (en) 2017-11-06 2018-11-05 Feline leukemia virus vaccine
US16/759,927 US11311616B2 (en) 2017-11-06 2018-11-05 Feline leukemia virus vaccine
BR112020008957-5A BR112020008957A2 (en) 2017-11-06 2018-11-05 vaccine against feline leukemia virus
EP18803572.9A EP3706788A1 (en) 2017-11-06 2018-11-05 Feline leukemia virus vaccine
AU2018358077A AU2018358077A1 (en) 2017-11-06 2018-11-05 Feline leukemia virus vaccine
RU2020118586A RU2784533C2 (en) 2017-11-06 2018-11-05 Vaccine against feline leukemia virus
CA3080427A CA3080427A1 (en) 2017-11-06 2018-11-05 Feline leukemia virus vaccine
US17/698,205 US12076392B2 (en) 2017-11-06 2022-03-18 Feline leukemia virus vaccine
JP2023135272A JP2023159327A (en) 2017-11-06 2023-08-23 feline leukemia virus vaccine

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762582050P 2017-11-06 2017-11-06
US62/5820,50 2017-11-06
US62/582,050 2017-11-06

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/759,927 A-371-Of-International US11311616B2 (en) 2017-11-06 2018-11-05 Feline leukemia virus vaccine
US17/698,205 Continuation US12076392B2 (en) 2017-11-06 2022-03-18 Feline leukemia virus vaccine

Publications (2)

Publication Number Publication Date
WO2019086646A1 WO2019086646A1 (en) 2019-05-09
WO2019086646A8 true WO2019086646A8 (en) 2020-06-04

Family

ID=64316486

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/080094 WO2019086646A1 (en) 2017-11-06 2018-11-05 Feline leukemia virus vaccine

Country Status (4)

Country Link
JP (2) JP2021501761A (en)
AU (1) AU2018358077A1 (en)
CA (1) CA3080427A1 (en)
WO (1) WO2019086646A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11167027B2 (en) 2017-11-06 2021-11-09 Intervet Inc. Multivalent feline vaccine
WO2021228731A1 (en) 2020-05-11 2021-11-18 Intervet International B.V. Feline severe acute respiratory syndrome coronavirus 2 vaccine
MX2023005495A (en) 2020-11-12 2023-05-23 Intervet Int Bv Recombinant vectors encoding chimeric coronavirus spike proteins and use thereof.
CN112852840A (en) * 2021-01-20 2021-05-28 西南民族大学 Niuxin-bur virus recombinant VP1 gene, recombinant protein and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE50304603D1 (en) * 2002-09-23 2006-09-21 Mologen Ag VACCINE AGAINST INFECTIONS WITH ONCOVIRES, SUCH AS THE FELINE LEUCOSE VIRUS OF THE CAT
US20050266550A1 (en) 2004-05-18 2005-12-01 Alphavax, Inc. TC-83-derived alphavirus vectors, particles and methods
ES2670813T3 (en) 2007-06-21 2018-06-01 Alphavax, Inc. Alphavirus Replicon Particles for Vaccination Use
US10004797B2 (en) * 2010-10-27 2018-06-26 Harrisvaccines, Inc. Method of rapidly producing improved vaccines for animals

Also Published As

Publication number Publication date
AU2018358077A1 (en) 2020-05-14
CA3080427A1 (en) 2019-05-09
JP2023159327A (en) 2023-10-31
WO2019086646A1 (en) 2019-05-09
JP2021501761A (en) 2021-01-21

Similar Documents

Publication Publication Date Title
USD757496S1 (en) Thermomug
WO2018109170A3 (en) Il-11ra antibodies
WO2018109174A3 (en) Il-11 antibodies
WO2015168019A3 (en) Anti-ptk7 antibody-drug conjugates
WO2016205531A3 (en) Anti-her2 antibodies and methods of use
WO2018081648A3 (en) Anti-mic antibidies and methods of use
EP3119432A4 (en) Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
WO2015179658A3 (en) Anti-gpc3 antibodies and immunoconjugates
EP3589731A4 (en) Coronaviruses, vaccines comprising the same, and methods for preventing disease
EP3488832A4 (en) Link member, and mouthpiece equipped with link member
EP3680331A4 (en) Modified cas9 protein, and use thereof
WO2019086646A8 (en) Feline leukemia virus vaccine
USD792319S1 (en) Anchor
SG11201908281VA (en) Phenalene-1-one-containing photosensitizer composition, phenalene-1-one compound and the use thereof
EP3654982A4 (en) 1,8-naphthyridinone compounds and uses thereof
EP3878956A4 (en) Modified cas9 protein, and use thereof
WO2016007540A3 (en) Compositions and methods for treating dengue virus infection
EP3618819A4 (en) Targeted drug rescue with novel compositions, combinations, and methods thereof
EP3543248A4 (en) PHOSPHORESCENT PtAg2 COMPLEX, PREPARATION METHOD THEREFOR AND USE THEREOF
USD754781S1 (en) Sunglasses
EP3715344A4 (en) 1,4-benzodiazapin-2-one derivatives and use thereof
EP3731837A4 (en) The combination comprising linagliptin and metformin
USD848117S1 (en) Trousers
IL280191A (en) Solubilized apyrases, methods and use
GB201810852D0 (en) Compositions, uses and methods

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18803572

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3080427

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020524369

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018358077

Country of ref document: AU

Date of ref document: 20181105

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018803572

Country of ref document: EP

Effective date: 20200608

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020008957

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112020008957

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20200505